DUBLIN--(BUSINESS WIRE)--The "Treanda - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Treanda - API Insight, 2019 provides product and API manufacturers' details across the globe along with the location.
The report gives the clear idea on the country wise DMF filed by worldwide companies related to Treanda. The report also highlights the patent details of Treanda.
Scope of the Report
- A comprehensive product overview including product description, regulatory milestones, safety, pharmacological properties, clinical trials, and product development activities have been elaborated in this report
- Patent information around Treanda in United States (US) and Europe (EU) has been highlighted
- API manufacturers for Treanda in United States, Europe, China and India
- The report contains historical and forecasted sales for Treanda till 2021
- Enlists the market competition and emerging therapies in the space where Treanda operates
Reasons to Buy
- Evaluate the marketing status of Treanda to exploit opportunities for generic Treanda development opportunities
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details with respect to Treanda
- API intelligence over Treanda and gaining primary intelligence over Active Ingredient manufacturers by country
- Make more informed business decisions from insightful and in-depth analysis of Treanda's performance
Topics Covered
1. Treanda Overview
2. Treanda Global Sales Assessment
- Treanda Historical Global Sales
- Treanda Forecasted Global Sales
3. Product Description
- Mechanism of Action
- Pharmacodynamic Properties
- Pharmacokinetic Properties
4. Product Details by country
5. Patent Information
6. Global API Manufacturers Assessment
- Active Pharmaceutical Ingredient (API) Manufacturers by Country
-
Active Pharmaceutical Ingredient (API) Manufacturers by Region
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fscsf3/treanda_api?w=4
